$100M to $250M is "sweet spot" for pharma venture funds

06/20/2013 | Genetic Engineering & Biotechnology News

Half of the 20 drugmaker venture capital funds on this list report total resources of between $100 million and $250 million. GlaxoSmithKline, Pfizer, Novartis, Sanofi, Merck and Boehringer Ingleheim are among the drugmakers starting or investing in venture capital funds for new drug discovery.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA